IMLYGIC (TALIMOGENE LAHERPAREPVEC)

Imlygic is a cancer medicine used to treat adults with melanoma (a type of skin cancer) that cannot be surgically removed and that has spread to other parts of the body (but not to bone, lung, brain and other internal organs).

Imlygic is a type of advanced therapy medicine called a ‘gene therapy product’. This is a type of medicine that works by delivering genes into the cells of the body. It contains the active substance talimogene laherparepvec.

Imlygic (Talimogene Laherparepvec) Injection suppliers in India. Allevaire India New Delhi, INDIA.

Alleviare Life sciences Pvt. Ltd. is a consulting pharmaceutical company specialized in providing medicines under Named Patient Program/Manage Access Program. Named Patient Program/ Manage Access Program is a program designed by the government of India and governments of many countries worldwide for patients who have exhausted the treatment options available in their respective countries and are in need of latest medicines that are available in countries of Europe and USA.

SOURCING:

Alleviare Life Sciences connects the buyer with the supplier who can ship Imlygic (Talimogene Laherparepvec) (Cancer Treatment Medicines) to any country of the world as per the buyer’s requirement and Government regulations of the country. Imlygic (Talimogene Laherparepvec) is manufactured by Amgen Inc.

Alleviare Life Sciences provides options for choosing exporter and supplier of Cancer treatment Medicines We take guarantee of quality and delivery anywhere in the world as per the buyer’s requirements.

The order for Imlygic (Talimogene Laherparepvec) Injection will be confirmed only after the receipt of valid prescription of doctor and import permit if applicable.

IMLYGIC is a genetically modified oncolytic viral therapy indicated for the local treatment of
unresectable cutaneous, subcutaneous, and nodal lesions in patients with melanoma recurrent after initial surgery.

Limitation of Use:

Imlygic has not been shown to improve overall survival or have an effect on visceral metastases.

Medicine Name: Imlygic
Generic Name: Talimogene Laherparepvec
Approval Date: Oct 27, 2015.
Available as (Form & Strength): Injection: 1 million PFU and 100 million PFU
Company Name: Amgen Inc.